Correlation Between Denali Therapeutics and Arvinas

Can any of the company-specific risk be diversified away by investing in both Denali Therapeutics and Arvinas at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Denali Therapeutics and Arvinas into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Denali Therapeutics and Arvinas, you can compare the effects of market volatilities on Denali Therapeutics and Arvinas and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Denali Therapeutics with a short position of Arvinas. Check out your portfolio center. Please also check ongoing floating volatility patterns of Denali Therapeutics and Arvinas.

Diversification Opportunities for Denali Therapeutics and Arvinas

0.84

Correlation Coefficient

Denali Therapeutics  Arvinas

Very poor diversification

The 3 months correlation between Denali and Arvinas is 0.84. Overlapping area represents the amount of risk that can be diversified away by holding Denali Therapeutics and Arvinas in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Arvinas and Denali Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Denali Therapeutics are associated (or correlated) with Arvinas. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Arvinas has no effect on the direction of Denali Therapeutics i.e., Denali Therapeutics and Arvinas go up and down completely randomly.

Pair Corralation between Denali Therapeutics and Arvinas

Given the investment horizon of 90 days Denali Therapeutics is expected to under-perform the Arvinas. But the stock apears to be less risky and, when comparing its historical volatility, Denali Therapeutics is 1.63 times less risky than Arvinas. The stock trades about -0.42 of its potential returns per unit of risk. The Arvinas is currently generating about -0.25 of returns per unit of risk over similar time horizon. If you would invest  2,508  in Arvinas on October 9, 2024 and sell it today you would lose (517.00) from holding Arvinas or give up 20.61% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Strong
Accuracy	100.0%
Values	Daily Returns

Denali Therapeutics  vs.  Arvinas

Denali Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Denali Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's essential indicators remain fairly strong which may send shares a bit higher in February 2025. The recent confusion may also be a sign of long-lasting up-swing for the firm traders.

Arvinas

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Arvinas has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in February 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Pair Trading with Denali Therapeutics and Arvinas

The main advantage of trading using opposite Denali Therapeutics and Arvinas positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Denali Therapeutics position performs unexpectedly, Arvinas can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Arvinas will offset losses from the drop in Arvinas' long position.

The idea behind Denali Therapeutics and Arvinas pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.